Drug Profile
Eblasakimab - ASLAN Pharmaceuticals
Alternative Names: ASLAN 004; CSL 334; IL-13R - Merck; IL-13Rα1 project; MK 6105Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Merck & Co; Zenyth Therapeutics
- Developer ASLAN Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors; Interleukin-13 receptor alpha1 subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Preclinical Chronic obstructive pulmonary disease
- No development reported Asthma
Most Recent Events
- 12 Apr 2024 Efficacy data from a phase IIb TREK-AD trial in Atopic dermatitis released by ASLAN Pharmaceuticals
- 11 Mar 2024 Updated efficacy and adverse events data from the phase II TREK-DX trial in Atopic dermatitis released by ASLAN Pharmaceuticals
- 06 Mar 2024 Preclinical trials in Chronic obstructive pulmonary disease in Singapore (Parenteral) , prior to March 2024